Isotechnika Pharma appoints Dr. Jurgen Engel to Board of Directors
17-Aug-2009
- Canada
Dr. Engel earned a doctorate degree in organic chemistry from the Technical University of Braunschweig, as well as an academic degree in pharmaceutical science from the University of Regensburg, where he is also a professor. In 1995, he was recognized for his development of alkylphospholipids as a new class of anti-tumor agents by receiving the Galenus-von-Pergamon Prize, an award that honors innovators in novel medicines.
Most read news
Organizations
Other news from the department people
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
Last viewed contents
DSM continues to invest in emerging biomedical companies
Go to page
SMEs to Benefit as Seventh Framework Research Programme is Adopted by European Parliament
Go to page
Arena Pharmaceuticals Granted Patent for Drug Screening Methods Related to Ortho McNeil, Inc. Collaboration
Go to page
Linde Material Handling GmbH - Aschaffenburg, Germany
Go to page
PanGenetics announces acquisition of PG110 anti-NGF antibody to treat chronic pain by Abbott
Go to page
Novartis and Alnylam Announce New Collaboration to Develop RNAi Therapeutics for Pandemic Flu
Go to page
Oncos Therapeutics Appoints Dr. Jonathan Knowles and Dr. Robert Burns to the Board of Directors
Go to page
Chemomedica Medizintechnik und Arzneimittel Vertriebsges.m.b.H. - Wien, Austria
Go to page
Lucidity - Matthews, USA
Go to page
Sunflower
Go to page
UTMB receives over $6 million to develop treatment for deadly Ebola and Marburg viruses
Go to page